title: Re: Daniel M. Geynisman. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol 2015;68:912-4.
authors.affiliation: Departments of Urology and Pathology, Indiana University School of Medicine, Indianapolis, IN, USA.
authors.forename: M Francesca
authors.initials: MF
authors.lastname: Monn
authors.affiliation: Departments of Urology and Pathology, Indiana University School of Medicine, Indianapolis, IN, USA.
authors.forename: Liang
authors.initials: L
authors.lastname: Cheng
authors.affiliation: Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy.
authors.forename: Marina
authors.initials: M
authors.lastname: Scarpelli
authors.affiliation: Department of Surgery, Cordoba University Medical School, Cordoba, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Lopez-Beltran
authors.affiliation: Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy. Electronic address: r.montironi@univpm.it.
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Montironi
mesh_terms: D000911:Antibodies, Monoclonal; D051017:Apoptosis Regulatory Proteins; D002292:Carcinoma, Renal Cell; D006801:Humans; D007680:Kidney Neoplasms; D000077594:Nivolumab
chemical_list: D000911:Antibodies, Monoclonal; D051017:Apoptosis Regulatory Proteins; D000077594:Nivolumab